Embla Medical hf. (OSSFF)
| Market Cap | 1.73B -20.2% |
| Revenue (ttm) | 958.30M +11.7% |
| Net Income | 85.63M +18.6% |
| EPS | 0.20 +19.1% |
| Shares Out | n/a |
| PE Ratio | 20.19 |
| Forward PE | 18.09 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,000 |
| Open | 4.150 |
| Previous Close | 4.300 |
| Day's Range | 4.150 - 4.150 |
| 52-Week Range | 4.150 - 5.325 |
| Beta | 0.45 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 21, 2026 |
About Embla Medical
Embla Medical hf., together with its subsidiaries, provides non-invasive orthopedic products in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. It operates through three segments: Prosthetics and Neuro Orthotics, Bracing and Supports, and Patient Care. The Prosthetics and Neuro Orthotics segment offers mechanical products, such as lower and upper limb loss or difference; and bionic products, such as microprocessor-controlled feet, knees, hands, fingers, and neuro orthotic joints. The Bracing and Supports segment provides os... [Read more]
Financial Performance
In 2025, Embla Medical's revenue was $928.69 million, an increase of 8.63% compared to the previous year's $854.89 million. Earnings were $83.34 million, an increase of 22.05%.
Financial StatementsNews
Embla Medical Slides: R&D presentation
Embla Medical has posted slides in relation to its latest quarterly earnings report, which was published on June 24, 2026.
Embla Medical Earnings Call Transcript: Q1 2026
Q1 2026 saw 15% revenue growth (4% organic), stable margins despite tariffs and FX, and 21% bottom-line growth. Guidance for 5%-8% organic growth and 20%-22% EBITDA margin is reiterated, with segment strength in Prosthetics and neuro-orthotics and recovery expected in Patient Care.
Embla Medical Quarterly report: Q1 2026
Embla Medical has published its Q1 2026 quarterly earnings report on April 28, 2026.
Embla Medical Slides: Q1 2026
Embla Medical has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 28, 2026.
Embla Medical Earnings Call Transcript: Q1 2026
Q1 2026 saw 15% reported sales growth and 21% net profit growth, with strong Prosthetics & Neuro Orthotics performance and margin pressure from FX and tariffs. Full-year guidance for 5%-8% organic growth and 20%-22% EBITDA margin is reiterated.
Embla Medical Quarterly report: Q1 2026
Embla Medical has published its Q1 2026 quarterly earnings report on April 28, 2026.
Embla Medical Slides: Q1 2026
Embla Medical has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 28, 2026.
Embla Medical Slides: Investor presentation
Embla Medical has posted slides in relation to its latest quarterly earnings report, which was published on April 28, 2026.
Embla Medical Transcript: Life Science-dagen 2026
A global leader in mobility solutions is driving growth through innovation, acquisitions, and expanding access to advanced prosthetics and neuro-orthotics. Key growth comes from functional trade-up, recurring sales, and new market penetration, while challenges include reimbursement, tariffs, and geopolitical risks.
Embla Medical Slides: FY 2026
Embla Medical has posted slides in relation to its FY 2026 quarterly earnings report, which was published on March 4, 2026.
Embla Medical Earnings Call Transcript: Q4 2025
Solid organic and acquisition-driven growth was achieved, with strong cash flow and resilient margins despite tariffs and FX headwinds. Guidance for 2026 anticipates 5%-8% organic growth and 20%-22% EBITDA margin, supported by efficiency gains and new product launches.
Embla Medical Annual report: Q4 2025
Embla Medical has published its Q4 2025 annual report on February 3, 2026.
Embla Medical Quarterly report: Q4 2025
Embla Medical has published its Q4 2025 quarterly earnings report on February 3, 2026.
Embla Medical Slides: Q4 2025
Embla Medical has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 3, 2026.
Embla Medical Earnings Call Transcript: Q4 2025
Solid organic sales growth of 6% for 2025 was driven by strong performance in prosthetics and neuroorthotics, with robust cash flow and a stable EBITDA margin. 2026 guidance targets 5%-8% organic growth and a 20%-22% EBITDA margin, with continued focus on patient care improvements and managing external headwinds.
Embla Medical Annual report: Q4 2025
Embla Medical has published its Q4 2025 annual report on February 3, 2026.
Embla Medical Quarterly report: Q4 2025
Embla Medical has published its Q4 2025 quarterly earnings report on February 3, 2026.
Embla Medical Slides: Q4 2025
Embla Medical has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 3, 2026.
Embla Medical Slides: Investor presentation
Embla Medical has posted slides in relation to its latest quarterly earnings report, which was published on February 3, 2026.
Embla Medical hf: Interim Report Q4 and Full Year 2025
COPENHAGEN, Denmark, Feb. 3, 2026 /PRNewswire/ -- Announcement no. 5/2026 Interim Report Q4 and Full Year 2025 Sveinn Sölvason, President and CEO, comments: "We delivered solid sales in the fourth qua...
Embla Medical Slides: SEB Nordic Seminar presentation
Embla Medical has posted slides in relation to its latest quarterly earnings report, which was published on January 9, 2026.
Embla Medical Slides: Investor presentation
Embla Medical has posted slides in relation to its latest quarterly earnings report, which was published on December 11, 2025.
Embla Medical Earnings Call Transcript: Q3 2025
Q3 2025 saw 7% organic and 11% reported sales growth, led by double-digit gains in prosthetics and neuroorthotics, while patient care and bracing/supports lagged. EBITDA margin held at 22%, and full-year guidance for 5%-6% organic growth and 20%-21% EBITDA margin was reiterated.
Embla Medical Quarterly report: Q3 2025
Embla Medical has published its Q3 2025 quarterly earnings report on October 21, 2025.
Embla Medical Slides: Q3 2025
Embla Medical has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on October 21, 2025.